Treatment
Cell clinical trials
We’re tracking 5,691 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT07304739RecruitingPhase 2
Furmonertinib plus radiation and chemo for EGFR lung cancer with brain spread
This trial tests a combination of a targeted pill (furmonertinib), chemotherapy into the spinal fluid, and precise radiation for people with a specific type of lung cancer (EGFR-mutant adenocarcinoma) that has spread to both the brain and the lining around the brain. The goal is to see if this combination can better control the cancer and improve symptoms.
Cangzhou, HebeiAges 18–75 - NCT07305090Recruiting
Gut GVHD biomarker study for transplant patients
This trial aims to develop a test using multiple biomarkers to predict how well patients will respond to treatment for acute graft-versus-host disease (GVHD) affecting the gut. It focuses on patients who are receiving an allogeneic stem cell transplant.
Bologna, BolognaAges 12 years+ - NCT07305337Recruiting
AI health education for blood cancer patients
This trial tests if an artificial intelligence (AI) program can help people with blood cancer learn about their condition and treatment. The goal is to see if AI-assisted education improves their understanding and care.
Wuhan, HubeiAges 18–90 - NCT07308457Recruiting
Comparing infection monitoring vs. antibiotic prevention in stem cell transplant
This trial compares two ways to prevent infections after a stem cell transplant: using a standard antibiotic (ceftriaxone) or closely watching for germs in the blood and treating only if needed. It aims to find which method is safer and more effective for people receiving a stem cell transplant.
Szczecin, West Pomeranian VoivodeshipAges 18 years+ - NCT07309497Recruiting
Geriatric Assessment for Older Adults Before CAR-T or Bispecific Therapy
This trial studies how a simple geriatric assessment (a check-up for older adults) can help predict side effects and outcomes in patients aged 65+ who are about to receive CAR-T cell therapy or bispecific antibody treatment.
BernAges 65 years+ - NCT07312864RecruitingPhase 1/Phase 2
New bioartificial liver for liver failure and small-for-size syndrome
This study tests a new bioartificial liver made from special cells to support people with severe liver problems, including liver failure or when the liver is too small after surgery. It aims to see if it is safe and can help the liver recover.
BeijingAges Any age - NCT07313982Recruiting
Leukemia study looking at LEF1 protein levels
This study is examining levels of a protein called LEF1 in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Researchers want to see if LEF1 can help predict survival and confirm diagnosis.
Bologna, BOLOGNAAges 18 years+ - NCT07315087RecruitingPhase 1
CAR T-cell therapy for autoimmune diseases
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
TianjinAges 18 years+ - NCT07317609RecruitingPhase 1
Immunotherapy plus chemo before endoscopic resection for esophageal cancer
This trial tests a treatment plan that combines immunotherapy with chemotherapy before possible endoscopic surgery. It is for people with a specific type of esophageal cancer that has not been treated before and is either potentially removable or not suitable for standard surgery.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07318259RecruitingPhase 1
Study of a new CAR-T therapy for lupus
This trial tests a fast-acting CAR-T therapy that targets BCMA and CD70 proteins to treat lupus. It may help people with moderate-to-severe lupus that hasn't improved with standard treatments.
Nanjing, JiangsuAges 18 years+ - NCT07320105RecruitingPhase 4
Radiation after surgery for lung cancer that spread to lymph nodes
This trial tests if giving radiation after surgery can help people with non-small cell lung cancer that has spread to multiple lymph nodes in the chest. It may offer a treatment option for those who have not had chemotherapy or immunotherapy before.
Fuzhou, FujianAges 18–75 - NCT07322718RecruitingEarly Phase 1
Testing RXIM002 for severe autoimmune diseases
This study tests a new drug called RXIM002 for people with severe autoimmune diseases that haven't improved with standard treatments. It aims to see if targeting immune cells with the CD19 marker can help control the disease.
Shanghai, Huangpu DistrictAges 18–65 - NCT07326280Recruiting
Cold ischemia robot-assisted partial nephrectomy trial
This trial studies a robot-assisted surgery to remove part of the kidney while keeping the kidney cool to protect it. It may help patients who need this type of kidney surgery.
Guangzhou, GuangdongAges 18–80 - NCT07328191Recruiting
Transfusion guided by quality of life for MDS or AML
This study is for people with MDS or AML who are not receiving treatment to cure the disease and need regular blood transfusions. It looks at whether using a quality-of-life questionnaire can guide transfusion decisions, to see if fewer transfusions can keep you feeling well.
NiceAges 18 years+ - NCT07329231Recruiting
Quinoa for early type 2 diabetes control
This study tests whether adding quinoa to your diet can help manage blood sugar and improve how your body uses insulin. It focuses on people recently diagnosed with type 2 diabetes.
Jinan, ShandongAges 20–70 - NCT07330596RecruitingPhase 2
Study of QL1706 plus chemo for lung cancer that got worse after immunotherapy
This trial tests a new drug called QL1706 combined with chemotherapy for people with non-small cell lung cancer that has spread or come back after previous treatment with an immunotherapy drug (PD-1/PD-L1 inhibitor) plus chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
HefeiAges 18–75 - NCT07331272RecruitingPhase 1
CAR T-cells for lupus and myositis
This trial tests a new treatment using your own immune cells (CAR T-cells) targeted at a marker called CD19. It is for people whose lupus or myositis has not been controlled by other treatments.
Bengbu, AnhuiAges 18–70 - NCT07331467RecruitingPhase 1
Ultra-fast CAR-T cell therapy for lupus
This trial tests a new CAR-T cell treatment for people with lupus who still have moderate to severe symptoms despite trying standard medications. It aims to quickly stop the immune system from attacking the body.
Nanjing, JiangsuAges 18 years+ - NCT07332858RecruitingPhase 1/Phase 2
Study of an experimental drug for lung cancer with fluid in the chest
This trial tests a new drug given directly into the chest cavity to treat fluid buildup caused by non-small cell lung cancer. It may help ease breathing problems and control the fluid.
Beijing, Beijing MunicipalityAges 18–75 - NCT07336732RecruitingPhase 2
New targeted drug with chemo for rare EGFR lung cancer
This trial tests a new targeted pill (andamertinib) with or without standard chemotherapy, compared to chemotherapy alone, for people with a rare type of EGFR-mutated lung cancer that has not been treated before. It aims to find which approach works better against the cancer.
GuangzhouAges 18 years+ - NCT07337096Recruiting
Electro-acupuncture for advanced lung cancer: the EALER study
This study tests whether adding electro-acupuncture (a gentle type of acupuncture with mild electrical pulses) to standard first-line immunotherapy and chemotherapy can help people with advanced non-small cell lung cancer. It aims to see if this combination improves quality of life and overall treatment outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT07337785RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a new kind of cell therapy (UCAR-T) that targets CD19 and BCMA proteins on immune cells. It is for people with certain neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, or autoimmune encephalitis who have not responded well to standard treatments.
Wuhan, HubeiAges 18–70 - NCT07339254Recruiting
Survey about immunotherapy for lung cancer patients
This study is a survey to learn about the experiences and feelings of people with non-small cell lung cancer who are taking immunotherapy drugs. The goal is to understand how you're doing on treatment, which can help improve care for others.
Los Angeles, CaliforniaAges 18 years+ - NCT07342179Recruiting
Monitoring immune cells after CAR-T therapy for myeloma
This study looks at how your immune system responds after you receive CAR-T cell therapy for multiple myeloma. The goal is to learn more about the treatment's effects and how well it works.
PoitiersAges 18 years+
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,691 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.